(+) Roche committed to innovation and growth (Roche) - Sep 5, 2012 - P1, N=99; NCT01209130; Preliminary data for RG7593 will be presented at investor conference; The data indicate very promising anti-tumor activity in pts with relapsed or refractory disease following treatment with anti-CD20 containing therapies
P1 data • Hematological Malignancies • Non-Hodgkin's Lymphoma
|
|
Roche has a total of nine ADCs in its development pipeline. Today, preliminary data for RG7593, a humanised IgG1 anti-CD22 monoclonal antibody (anti-CD22) conjugated to an anti-mitotic agent, will be presented. RG7593 is currently being tested in phase I in haematological cancers. The data indicate very promising anti-tumour activity in patients with relapsed or refractory disease following treatment with anti-CD20 containing therapies.
(IR4)
|